| 000 | 01899 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517142405.0 | ||
| 264 | 0 | _c20180116 | |
| 008 | 201801s 0 0 eng d | ||
| 022 | _a1432-1041 | ||
| 024 | 7 |
_a10.1007/s00228-017-2226-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLee, Sun Ku | |
| 245 | 0 | 0 |
_aSafety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical pharmacology _cJun 2017 |
||
| 300 |
_a689-698 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAgammaglobulinaemia Tyrosine Kinase |
| 650 | 0 | 4 |
_aAntigens, CD _xmetabolism |
| 650 | 0 | 4 |
_aAntigens, Differentiation, T-Lymphocyte _xmetabolism |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoquinolines _xadministration & dosage |
| 650 | 0 | 4 |
_aLectins, C-Type _xmetabolism |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOligopeptides _xadministration & dosage |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aXing, Jun | |
| 700 | 1 | _aCatlett, Ian M | |
| 700 | 1 | _aAdamczyk, Robert | |
| 700 | 1 | _aGriffies, Amber | |
| 700 | 1 | _aLiu, Ang | |
| 700 | 1 | _aMurthy, Bindu | |
| 700 | 1 | _aNowak, Miroslawa | |
| 773 | 0 |
_tEuropean journal of clinical pharmacology _gvol. 73 _gno. 6 _gp. 689-698 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00228-017-2226-2 _zAvailable from publisher's website |
| 999 |
_c26941403 _d26941403 |
||